Drug Approval | December 27, 2025
EU nod to Wayrilz as breakthrough treatment for hard-to-treat ITP
Wayrilz represents a new approach to ITP by targeting the disease at its root through multi-immune modulation
Wayrilz represents a new approach to ITP by targeting the disease at its root through multi-immune modulation
The drug had previously received orphan drug designation for this rare cancer on March 31, 2025
This production milestone positions Symbiosis at the forefront of meeting rising global demand for life-saving medicines
The SAPIEN M3 transcatheter mitral valve replacement (TMVR) system is designed for patients with symptomatic moderate-to-severe or severe MR
Masitinib targets mast cells, which play a critical role in severe forms of SCD and its complications, including vaso-occlusive crises, acute chest syndrome, and pain
The decision is based on robust clinical evidence from the VOYAGE and EXCURSION studies
Afrezza comes in single-use cartridges, delivered via a simple inhaler device. Users select the appropriate cartridge, load it, inhale the insulin, and remove the cartridge
U.S. and Canada transaction supports continued access to RADICAVA for people living with ALS
The therapy targets the LRRC15 protein and is designed for enhanced tumor penetration and differentiated anti-tumor activity in solid tumors with the highest unmet needs.
Provides pain relief for more than 30 conditions, including chronic back pain, arthritis, and sports injuries
Subscribe To Our Newsletter & Stay Updated
